PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death.The PARP family consists of 17 individuals. They are all very different in terms of their cell structures and functions. There is confirmed PARP activity in the following proteins: PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2). Additional genes include PARP3, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. The nucleus of the cell contains PARP. The primary responsibility is to identify and alert the enzymatic machinery responsible for SSB repair to single-strand DNA breaks (SSB).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2692 | NMS-P118 | 1262417-51-5 | NMS-P118 is a novel potent, orally available, and highly selective PARP-1 (protein poly(ADP-ribose) polymerase-1) inhibitor with150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively). |
|
V0308 | NU1025 | 90417-38-2 | NU1025 is a novel, potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP) inhibitor with potential anticancer activity. |
|
V0300 | Olaparib (AZD2281; KU0059436) | 763113-22-0 | Olaparib (formerly also known as AZD-2281; KU-59436; KU0059436; trade name Lynparza) is a potent,novel and orally bioavailable small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential anticancer activity. |
|
V51025 | OM-153 | 2406278-81-5 | OM-153 is a novel and selective inhibitor of tankyrase that has IC50 values for tankyrase 1 and tankyrase 2 (TNKS1/2) of 13 nM and 2 nM, respectively. |
|
V41066 | OM-1700 | 2406276-78-4 | OM-1700 is a novel inhibitor of tankyrase with IC50s of 127 and 14 nM for tankyrase 1 and tankyrase 2, respectively. |
|
V51287 | OUL-232 | 943119-42-4 | OUL232 is a novel and selective inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15. OUL232 is the first PARP12 inhibitor to be reported and the most potent PARP10 inhibitor to date (IC50=7.8 nM). |
|
V51298 | OUL-245 | 1023814-45-0 | OUL245, derivative of 7-Hydroxy, and a selectively PARP2 inhibitor (IC50=44 nM). |
|
V3280 | Pamiparib | 1446261-44-4 | Pamiparib (also known as BGB-290; trade name in China: Baihuize) is a novel, potent and selective inhibitor of PARP1/2 approved in China for cancer treatment. |
|
V3281 | Pamiparib maleate | 2086689-94-1 | Pamiparib maleate, the maleate salt of pamiparib (formerly BGB-290), is a selective inhibitor of PARP1 and PARP2with IC50 values of 0.83 and 0.11 nM, respectively. |
|
V75779 | PARP-1-IN-1 | 2763840-83-9 | PARP-1-IN-1 is a selective and orally bioactive PARP-1 inhibitor (IC50=0.96 nM). |
|
V81046 | PARP-1-IN-13 | PARP-1-IN-13 (Compound 19c) is a PARP-1 inhibitor (IC50= 26 nM). | |
|
V51272 | PARP-1-IN-4 | 684234-56-8 | PARP-1-IN-4 is a novel and selective inhibitor of PARP-1. |
|
V51281 | PARP-1/2-IN-1 | 1903744-45-5 | PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor (antagonist) with IC50 of 0.51nm and 23.11nm respectively. |
|
V81044 | PARP-1/2-IN-2 | PARP-1/2-IN-2 (Compound 12e) is a PARP1/2/CDK12 inhibitor (IC50= 34, 30, and 285 nM, respectively). | |
|
V81045 | PARP-1/Proteasome-IN-1 | PARP-1/Proteasome-IN-1 (compound 42i) is a dual (bifunctional) inhibitor of PARP-1 and proteasome, which has a significant inhibitory effect on breast cancer. | |
|
V51277 | PARP-2-IN-2 | 2915651-00-0 | PARP-2-IN-2 (compound 27) is an inhibitor PARP‑2 with an IC50 value of 0.057 µM. In MCF-7 breast cancer cells, PARP-2-IN-2 causes cell cycle arrest and apoptosis. |
|
V51276 | PARP-2/1-IN-2 | 912444-01-0 | PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a novel PARP inhibitor with Kis values of 2 and 5 nM against PARP-2 and PARP-1, respectively. |
|
V0306 | PARP-IN-1 (3-aminobenzamide; 3-ABA; 3-AB) | 3544-24-9 | PARP-IN-1(3-Aminobenzamide; 3-ABA; 3-AB) is a novel and potent inhibitor of PARP [Poly(ADP-ribose)polymerase] with potential anticancer activity. |
|
V51283 | PARP/EZH2-IN-1 | 2687273-52-3 | PARP/EZH2-IN-1 is the first dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA that has been found to be effective. |
|
V80290 | PARP1-IN-15 | PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
